Tilray Medical has expanded its medical cannabis offerings in the UK, now offering the broadest portfolio of cannabis flower on the UK market.
The Canadian cannabis company Tilray Medical has expanded its portfolio of medical cannabis products, which now includes a differentiated range of high THC products cultivated at Tilray’s EU-GMP-certified facility in Portugal.
Tilray Medical now offers an extensive selection of medical cannabis products including a portfolio of cannabis flowers with THC potencies that span from 10 per cent to 25 per cent and offer a range of different ratios.
Denise Faltischek, Tilray’s chief strategy officer and head of international business, said, “The demand for medical cannabis in the UK is growing rapidly. We are incredibly proud to provide patients in the UK with high-quality, consistent medical cannabis products they can rely on and are accessible to them.”
Tilray Medical’s portfolio in the UK is underpinned by a breadth of cultivars, each with a unique profile of cannabinoids and terpenes that have been selected to ensure a consistent supply. The company said it hopes to further expand the range of treatment options available to patients in the UK.
The Canadian firm supplies the UK and the rest of its international business with EU-GMP-certified medical cannabis from its state-of-the-art facilities in Portugal, providing patients with safe and reliable access to high-quality medical cannabis.
Tilray has grown from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first EU-GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany.
Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, working across 20 countries.
